Inhibitor Development and Activated Factor VIII in Concentrates

• References

• 1 Peerlinck K, Arnout J, Gilles JG, Saint-Remy J-M, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurised factor VIII concentrate. Thromb Haemost 1993; 69 (02) 115-118
• 2 Rosendaal FR, Nieuwenhuis HK, van denBerg HM, Heijboer H, Maurer-Bunschoten EP, van derMeer J, Smit C, Strengers PFW, Briet E. the Dutch Hemophilia Study Group. A sudden increase in Factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81 (08) 2180-2186
• 3 Barrowcliffe TW, Watton J, Harman A, Tubbs JE, Kemball-Cook G. Potency of high purity factor VIII concentrates. Lancet 1990; ii: 124
• 4 Barrowcliffe TW, Dawson NJ, Kemball-Cook G. Activated factor VIII in concentrates prepared by monoclonal antibody and recombinant technology. Thromb Haemost 1989; 62 (01) 198
• 5 Kemball-Cook G, Tubbs JE, Dawson NJ, Barrowcliffe TW. The behaviour of different factor VIII concentrates in a chromogenic factor X-activating system. Brit J Haemat 1993; 84: 273-278
• 6 Tubbs JE, Kemball-Cook G, Barrowcliffe TW. Effects of von Willebrand factor and phospholipid on co-factor activity of factor VIII in concentrates. Thromb Haemost 1991; 65 (06) 944